Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

Shares of Abbott Laboratories advanced 3.74% to $131.35 Thursday, on what proved to be an all-around poor trading session for ...

In a report released on March 27, Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

We recently published a list of the 10 Best S&P 500 Stocks to Buy for Dividend Growth. In this article, we are going to take ...

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s ...

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.

If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...